HOME
>
薬学
>
雑誌
> 医学と薬学　71/10　2014年10月号

医学と薬学　71/10　2014年10月号

出版社：	自然科学社
発行日：	2014-09-27
分野：	薬学 > 雑誌
ISSN：	03893898
雑誌名：	医学と薬学
特集：	消化器がん化学療法の最先端
電子書籍版：	2014-09-27 （第1版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

品切れ

2,200 円(税込)

電子書籍

章別単位での購入はできません

ブラウザ、アプリ閲覧

1,100 円(税込)

購入する

医学と薬学　71/10　2014年10月号

―目次―

特集　消化器がん化学療法の最先端

序文
食道癌
胃癌
大腸癌
消化管間質腫瘍（GIST）の分子標的治療
消化管悪性リンパ腫
胆道癌
膵癌
膵・消化管神経内分泌腫瘍（NET）の化学療法
消化器がんと緩和医療

前臨床試験
　レボフロキサシン点眼液1.5％「日医工」の生物学的同等性試験
　　−ウサギを用いた薬力学的同等性の評価−

臨床試験
　ロスタゾールOD錠50mg「トーワ」およびシロスタゾールOD錠
　　100mg「トーワ」の日本人健康成人男性における生物学的同等性
　オロパタジン塩酸塩顆粒0.5％「トーワ」の日本人健康成人男性
　　における生物学的同等性

臨床報告
　2型糖尿病患者における他のGLP-1製剤から持続性エキセナチド
　　への切り替えの有用性の検討

Diagnosis
　質の良いHbA1cとしての新しい血糖変動指標“ADRR”
　HCV抗体プロファイル検査試薬の開発と性能評価
　ヒト心臓由来脂肪酸結合蛋白（H-FABP）定量測定の有用性
　A群β溶血性レンサ球菌抗原迅速診断薬
　　クイックナビ?-Strep Aの評価
　イムノクロマトグラフィーを用いた
　　ノロウイルス迅速診断キットの臨床評価
　自己抗体測定試薬エリアミトコンドリアM2の臨床的有用性
　クレアチンキナーゼアイソザイムキット
　　「Lタイプワコー CK-MB mass」の基礎的検討

Cosmetic
　薬用オールインワンジェルの美白効果

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集消化器がん化学療法の最先端】

P.1759 掲載の参考文献

1) Van Cutsem E, Moiseyenko VM, Tjulandin S et al : Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer : a report of the V325 Study Group. J Clin Oncol 24 (31) : 4991-4997, 2006.

2) Herskovic A, Martz K, al-Sarraf M et al : Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326 (24) : 1593-1598, 1992.

PubMed

3) al-Sarraf M, Martz K, Herskovic A et al : Pro-gress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer : an intergroup study. J Clin Oncol 15 (1) : 277-284, 1997.

4) Kato H, Sato A, Fukuda H et al : A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma : Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol 39 (10) : 638-643, 2009.

5) Iizuka T, Kakegawa T, Ide H et al : Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus : a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 22 (3) : 172-176, 1992.

PubMed

6) Kato K, Tahara M, Hironaka S et al : A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 67 (6) : 1265-1272, 2011.

PubMed

7) Conroy T, Galais MP, Raoul JL et al : Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17) : final results of a randomised, phase 2/3 trial. Lancet Oncol 15 (3) : 305-314, 2014.

PubMed

8) van Hagen P, Hulshof MC, van Lanschot JJ et al : Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366 (22) : 2074-2084, 2012.

9) Ciardiello F, Tortora G : EGFR antagonists in cancer treatment. N Engl J Med 358 (11) : 1160-1174, 2008.

PubMed

10) Kitagawa Y, Ueda M, Ando N et al : Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 2 (5) : 909-914, 1996.

PubMed

11) Bonner JA, Harari PM, Giralt J et al : Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer : 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11 (1) : 21-28, 2010.

PubMed

12) Burtness B, Goldwasser MA, Flood W et al : Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer : an Eastern Cooperative Oncology Group study. J Clin Oncol 23 (34) : 8646-8654, 2005.

13) Crosby T, Hurt CN, Falk S et al : Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1) : a multicentre, phase 2/3 randomised trial. Lancet Oncol 14 (7) : 627-637, 2013.

14) Ilson DH, Kelsen D, Shah M et al : A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 117 (7) : 1409-1414, 2011.

15) Topalian SL, Hodi FS, Brahmer JR et al : Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (26) : 2443-2454, 2012.

PubMed

16) Ohigashi Y, Sho M, Yamada Y et al : Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11 (8) : 2947-2953, 2005.

PubMed

P.1767 掲載の参考文献

1) Boku N, Ohtsu A, Shimada Y et al : Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. Lancet Oncol 10 (11) : 1063-1069, 2009.

2) Koizumi W, Narahara H, Hara T et al : S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial) : a phase III trial. Lancet Oncol 9 (3) : 215-221, 2008.

3) Narahara H, Iishi H, Imamura H et al : Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 14 (1) : 72-80, 2011.

4) Kim WH, Koizumi W, LeeKH et al : Randomized phase III study of S-1 alone versus S-1 plus docetaxel in the treatment for advanced gastric cancer : The START trial. Presente d at the ASCO GI symposium San Francisco, CA, 2011. Abstract 7.

5) Kang YK, Kang WK, Shin DB et al : Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer : a randomised phase III noninferiority trial. Ann Oncol 20 : 666-673, 2009.

PubMed

6) Bang YJ, Van Cutsem E, Feyereislova A et al : Trastzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA) : Phase 3, open-label, randomizedcontrolledtrial. Lancet Oncol 10 : 1063-1069, 2009.

7) Kurokawa Y, Sugimoto N, Miwa H et al : Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer 110 (5) : 1163-1168, 2014.

8) Tamura S, Miki H, Nakata K et al : Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer. Gastric Cancer 10 : 251-255, 2007.

9) Ishigami H, Kitayama J, Otani K et al : Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology 76 : 311-314, 2009.

10) Ishigami H, Kitayama J, Kaisaki S et al : Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 21 : 67-70, 2010.

11) Van Cutsem E, Moiseyenko VM, Tjulandin S et al : Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer : a report of the V325 Study Group. J Clin Oncol 24 : 4991-4997, 2006.

12) Koizumi W, Takiuchi H, Yamada Y et al : Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol 21 : 1001-1005, 2010.

13) Higuchi K, Koizumi W, Yamada Y et al : Randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin for first-line treatment of advanced gastric cancer. J Clin Oncol 30 (suppl 34 : abstr 60), 2012

14) Sakuramoto S, Sasako M, Yamaguchi T et al : ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oralfluoropyrimidine. N Engl J Med 357 : 1810-1820, 2007.

15) Sasako M, Sakuramoto S, Katai H et al : Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29 : 4387-4393, 2011.

PubMed

16) Bang YJ, Kim YW, Yang HK et al : CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC) : a phase 3 open-label, randomised controlled trial. Lancet 379 : 315-321, 2012.

PubMed

P.1773 掲載の参考文献

1) Koizumi W, Boku N, Yamaguchi K et al : Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Ann Oncol 21 : 766-771, 2010.

PubMed

2) Yoshino T, Mayer R, Falcone A et al : Results of a multicenter, randomized, double-blind, phase III study of TAS-102 vs. placebo, with betst supportive care (BSC), in patients (PTS) with metastatic colorectal cancer (MCRC) refractory to standard therapies (RECOURSE). Ann Oncol 25 (suppl 2) : ii114 doi : 10.1093/annonc/mdu193.22

3) Grothey A, Van Cutsem E, Sobrero A et al : Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 : 303-312, 2013.

PubMed

4) Schmoll HJ, Van Cutsem E, Stein A et al : ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23 : 2479-2516, 2012.

PubMed

5) ガイドライン作成委員会 : 大腸癌治療ガイドライン, 金原出版, 東京, 2014.

6) Yamada Y, Takahari D, Matsumoto H et al : Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT) : an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14 : 1278-1286, 2013.

PubMed

7) Hecht JR, Mitchell E, Chidiac T et al : A randomized phase III B trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27 : 672-680, 2009.

8) http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/

9) Douillard JY, Oliner KS, Siena S et al : Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369 : 1023-1034, 2013.

PubMed

10) Stintzing S, Jung A, Rossius L et al : Analysis of KRAS/NRAS and BRAF mutations in FIRE-3. ESMO 2013 #LBA17.

11) Kato T, Ohashi Y, Nakazato H et al : Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer : multicenter prospective randomized trial. Langenbeck's archives of surgery/Deutsche Gesellschaft fur Chirurgie 386 : 575-581, 2002.

12) Sakamoto J, Hamada C, Yoshida S et al : An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. Br J Cancer 96 : 1170-1177, 2007.

PubMed

13) Allegra CJ, Yothers G, O'Connell MJ et al : Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon : results of NSABP protocol C-08. J Clin Oncol 29 : 11-16, 2011.

PubMed

14) Van Cutsem E, Labianca R, Bodoky G et al : Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer : PETACC-3. J Clin Oncol 27 : 3117-3125, 2009.

PubMed

15) Yoshida M, Ishiguro M, Ikejiri K et al : S-1 as adjuvant chemotherapy for stage III colon cancer : a randomized phase IIItudy (ACTS-CC trial). Ann Oncol, 2014 Jun 18. pii : mdu232 [Epub ahead of print]

16) Andre T, Boni C, Navarro M et al : Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27 : 3109-3116, 2009.

17) Yothers G, O'Connell MJ, Allegra CJ et al : Oxaliplatin as adjuvant therapy for colon cancer : updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29 : 3768-3774, 2011.

PubMed

P.1781 掲載の参考文献

1) Demetti GD, Benjamin R, Blanke CD et al : NCCN task force report : optimal management of patients with gastrointestinal stromal tumor (GIST) -expansion and update of NCCN clinical practice guidelines. J Natl Compr Cancer Net 2 (Suppl 1) : S1-26, 2004.

2) Blay J-Y, Bonvalot S, Casali P et al : for the GIST Consensus Meeting Panelists. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 16 : 566-578, 2005.

PubMed

3) 日本癌治療学会, 日本胃癌学会, GIST研究会編 : GIST診療ガイドライン, 金原出版, 東京, 2008.

4) 日本癌治療学会GISTガイドライン委員会 : GIST診療ガイドライン, http://www.jsco-cpg.jp/item/03/index.html

5) Hirota S, Isozaki K, Moriyama Y et al : Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 : 577, 1998.

PubMed

6) Nakai N, Ishikawa T, Nishitani A et al : A mouse model of a human multiple GIST family with KIT-Asp820Tyr mutation generated by a knock-in strategy. J Pathol 214 : 302, 2008.

PubMed

7) Heinrich MC, Corless CL, Duensing A et al : PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors. Science 299 : 708, 2003.

PubMed

8) Hirota S, Ohashi A, Nishida T et al : Gain-of-mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125 : 660, 2003.

PubMed

9) Miwa S, Nakajima T, Murai Y et al : Mutation assay of the novel gene DOG1 in gastrointestinal stromal tumors (GISTs). J Gastroenterol 43 : 53, 2008.

10) Demetri GD, von Mehren M, Blanke CD et al : Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl J Med 347 : 472, 2002.

PubMed

11) Saito S, Nakata K, Kajiura S et al : Long-Term Follow-Up Outcome of Imatinib Mesylate Treatment for Recurrent and Unresectable Gastrointestinal Stromal Tumors Digestion 87 : 47-52, 2013.

PubMed

12) Blanke CD, Demetri GD, von Mehren M et al : Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26 : 620, 2008.

PubMed

13) Nishida T, Shirao K, Sawaki A et al : Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors : a phase II study (STI571B1202). Int J Clin Oncol 13 : 244, 2008.

PubMed

14) Demetri GD, van Oosterom AT, Garrett CR et al : Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib : a randomised controlled trial. Lancet 368 : 1329, 2006.

PubMed

15) Demetri GD, Reichardt P, Kang YK et al : Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID) : an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 : 295-302, 2013.

PubMed

16) Heinrich MC, Corless CL, Demetri GD et al : Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 : 4342, 2003.

PubMed

P.1790 掲載の参考文献

1) Nakamura S, Matsumoto T, Iida M et al : Primary gastrointestinal lymphoma in Japan : a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer 97 : 2462-2473, 2003.

PubMed

2) d'Amore F, Brincker H, Gronbaek K et al : Non-Hodgkin's lymphoma of the gastrointestinal tract : a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group. J Clin Oncol 12 : 1673-1684, 1994.

3) Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 52 : 1410-1416, 1983.

PubMed

4) Cohen SM, Petryk M, Varma M et al : Non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue. Oncologist 11 : 1100-1117, 2006.

PubMed

5) Fischbach W, Goebeler ME, Ruskone-Fourmestraux A et al : Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy : experience from a large international series. Gut 56 : 1685-1687, 2007.

PubMed

6) Goda JS, Gospodarowicz M, Pintilie M et al : Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer 116 : 3815-3824, 2010.

PubMed

7) Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 16 : 1916-1921, 1998.

PubMed

8) Koch P, del Valle F, Berdel WE et al : Primary gastrointestinal non-Hodgkin's lymphoma : II. Combined surgical and conservative or conservative management only in localized gastric lymphoma-results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol 19 : 3874-3883, 2001.

PubMed

9) Nakamura S, Sugiyama T, Matsumoto T et al : Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori : a multicentre cohort follow-up study of 420 patients in Japan. Gut 61 : 507-513, 2012.

PubMed

10) Solal-Celigny P, Lepage E, Brousse N et al : Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med 329 : 1608-1614, 1993.

11) Hiddemann W, Kneba M, Dreyling M et al : Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advancedstage follicular lymphoma compared with therapy with CHOP alone : results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106 : 3725-3732, 2005.

12) Yoshino T, Miyake K, Ichimura K et al : Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol 24 : 688-693, 2000.

PubMed

13) 品川慶, 北台靖彦, 児玉美千世他 : 【消化管悪性リンパ腫2014】消化管原発low-grade lymphoma濾胞性リンパ腫とマントル細胞リンパ腫濾胞性リンパ腫の診断と治療診断. 胃と腸 49 : 656-663, 2014.

14) Kodama M, Kitadai Y, Shishido T et al : Primary follicular lymphoma of the gastrointestinal tract : a retrospective case series. Endoscopy 40 : 343-346, 2008.

PubMed

15) 長屋匡信, 奥原禎久, 大工原誠一他 : 【消化管悪性リンパ腫2014】消化管原発low-grade lymphoma濾胞性リンパ腫とマントル細胞リンパ腫濾胞性リンパ腫の診断と治療消化管原発濾胞性リンパ腫の治療積極的に治療を行う立場から. 胃と腸 49 : 676-685, 2014.

16) 田利晶, 麻奥英毅, 藤原恵他 : 【消化管悪性リンパ腫2014】消化管原発low-grade lymphoma濾胞性リンパ腫とマントル細胞リンパ腫濾胞性リンパ腫の診断と治療腸管原発濾胞性リンパ腫の治療 "watch and wait" の立場から. 胃と腸 49 : 664-674, 2014.

17) Ardeshna KM, Qian W, Smith P et al : Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma : an open-label randomised phase 3 trial. Lancet Oncol 15 : 424-435, 2014.

PubMed

18) Aviles A, Nambo MJ, Neri N et al : The role of surgery in primary gastric lymphoma : results of a controlled clinical trial. Ann Surg 240 : 44-50, 2004.

PubMed

19) Miller TP, Dahlberg S, Cassady JR et al : Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and highgrade non-Hodgkin's lymphoma. N Engl J Med 339 : 21-26, 1998.

PubMed

20) dos Santos LV, Lima JP, Lima CS et al : Is there a role for consolidative radiotherapy in the treatment of aggressive and localized non-Hodgkin lymphoma? A systematic review with meta-analysis. BMC Cancer 12 : 288, 2012.

21) Tari A, Asaoku H, Kashiwado K et al : Predictive value of endoscopy and endoscopic ultrasonography for regression of gastric diffuse large B-cell lymphomas after Helicobacter pylori eradication. Dig Endosc 21 : 219-227, 2009.

22) Coiffier B, Lepage E, Briere J et al : CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 : 235-242, 2002.

PubMed

P.1796 掲載の参考文献

1) 胆道癌診療ガイドライン作製出版委員会編 : エビデンスに基づいた胆道癌診療ガイドライン, 第1版, 高田忠敬編, 医学図書出版, 東京, 2007.

2) Miyakawa S, Ishihara S, Horiguchi A et al : Biliary tract cancer treatment : 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 16 (1) : 1-7, 2009.

PubMed

3) 日本肝胆膵外科学会編 : 臨床・病理胆道癌取扱い規約, 第6版, 金原出版, 東京, 2013.

4) 日本肝癌肝癌研究会編 : 臨床・病理原発性肝癌取扱い規約, 第5版補訂版, 金原出版, 東京, 2009.

5) Okusaka T, Ishii H, Funakoshi A et al : Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 57 (5) : 647-653, 2006.

PubMed

6) Furuse J, Okusaka T, Boku N et al : S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer : a multicenter phase II study. Cancer Chemother Pharmacol 62 (5) : 849-855, 2008.

PubMed

7) Valle JW, Wasan H, Johnson P et al : Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours : a multicentre randomised phase II study?The UK ABC-01 Study. Br J Cancer 101 (4) : 621-627, 2009.

8) Valle J, Wasan H, Palmer DH et al : Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362 (14) : 1273-1281, 2010.

PubMed

9) Furuse J, Okusaka T, Bridgewater J et al : Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. Crit Rev Oncol Hematol 80 (1) : 31-39, 2011.

PubMed

10) Morizane C, Okusaka T, Mizusawa J et al : Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer : a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci 104 (9) : 1211-1216, 2013.

11) Ebata T, Yokoyama Y, Igami T et al : Hepatopancreatoduodenectomy for cholangiocarcinoma : a single-center review of 85 consecutive patients. Ann Surg 256 (2) : 297-305, 2012.

PubMed

12) Nagino M, Nimura Y, Nishio H et al : Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma : an audit of 50 consecutive cases. Ann Surg 252 (1) : 115-123, 2010.

PubMed

13) Sasaki T, Isayama H, Nakai Y et al : A pilot study of salvage irinotecan monotherapy for advanced biliary tract cancer. Anticancer research 33 (6) : 2619-2622, 2013.

PubMed

14) Moretto R, Raimondo L, De Stefano A et al : FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma : a monoinstitutional experience. Anti-cancer drugs 24 (9) : 980-985, 2013.

15) He S, Shen J, Sun X et al : A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. Journal of chemotherapy 26 (4) : 243-247, 2014.

16) Zhu AX, Meyerhardt JA, Blaszkowsky LS et al : Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome : a phase 2 study. Lancet Oncol 11 (1) : 48-54, 2010.

PubMed

17) Gruenberger B, Schueller J, Heubrandtner U et al : Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer : a phase 2 study. Lancet Oncol 11 (12) : 1142-1148, 2010.

PubMed

18) Malka D, Cervera P, Foulon S et al : Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO) : a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol 15 (8) : 819-828, 2014.

PubMed

19) Lee J, Park SH, Chang HM et al : Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer : a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 13 (2) : 181-188, 2012.

PubMed

20) 工藤正俊, 有井滋樹, 猪飼伊和夫他 : 第18回全国原発性肝癌追跡調査報告 (2004-2005) (日本肝癌研究会追跡調査委員会). 肝臓 [解説] 51 (8) : 460-484, 2010.

21) Takada T, Amano H, Yasuda H et al : Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95 (8) : 1685-1695, 2002.

PubMed

22) Murakami Y, Uemura K, Sudo T et al : Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 250 (6) : 950-956, 2009.

23) Neoptolemos JP, Moore MJ, Cox TF et al : Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma : the ESPAC-3 periampullary cancer randomized trial. JAMA 308 (2) : 147-156, 2012.

PubMed

24) Horgan AM, Amir E, Walter T et al : Adjuvant therapy in the treatment of biliary tract cancer : a systematic review and meta-analysis. J Clin Oncol 30 (16) : 1934-1940, 2012.

PubMed

P.1807 掲載の参考文献

1) 癌研究振興財団 : 癌統計 '13. http://ganjoho.jp/data/professional/statistics/backnumber/2013/cancer_statistics_2013.pdf. (2014.7.26アクセス)

2) 日本膵臓学会膵癌診療ガイドライン改訂委員会 : 膵癌診療ガイドライン2013年版の一部改訂について. http://www.suizou.org/2014/news-11.html. (2014.7.26アクセス)

3) Burris HA 3rd, Moore MJ, Andersen J et al : Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 15 : 2403-2413, 1997.

4) Moore MJ, Goldstein D, Hamm J et al : Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 : 1960-1966, 2007.

5) Okusaka T, Furuse J, Funakoshi A et al : Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 102 : 425-431, 2011.

PubMed

6) Ueno H, Ioka T, Ikeda M et al : Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan : GEST Study. J Clin Oncol 31 : 1640-1648, 2013.

PubMed

7) Conroy T, Desseigne F, Ychou M et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 : 1817-1825, 2011.

PubMed

8) Okusaka T, Ikeda M, Fukutomi A et al : Phase II study of FOLFIRINOX for metastatic chemotherapy-naive Japanese pancreatic cancer patients. Cancer Sci (in press)

9) Ueno H, Okusaka T, Furuse J et al : Multicenter Phase II Study of Gemcitabine and S-1 Combination Therapy (GS Therapy) in Patients With Metastatic Pancreatic Cancer. Jpn J Clin Oncol 41 : 953-958, 2011.

PubMed

10) Ishii H, Okusaka T, Ikari T et al : Efficacy and safety of Gemcitabine plus S-1 treatment in locally advanced and metastatic pancreatic cancer : A pooled analysis of three randomized trials using updated individual patient data. The European Cancer Congress 2013. Abstr 2595.

11) Von Hoff DD, Ramanathan RK, Borad MJ et al : Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer : a phase I/II trial. J Clin Oncol 29 : 4548-4554, 2011.

12) Von Hoff DD, Ervin T, Arena FP et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 : 1691-1703, 2013.

PubMed

13) Ikeda M, Ueno H, Ueno M et al : A phase I/II trial of weekly nab-paclitaxel (nab-P) + Gemcitabine (GEM) in Japanese patients (pts) with metastatic pancreatic cancer (MPC). 第12回日本臨床腫瘍学会学術集会, 2014.7.17.

14) Pelzer U, Schwaner I, Stieler J et al : Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouraci (l OFF) plus BSC in patients for second-line advanced pancreatic cancer : A phase III-study from the German CONKO-study group. Eur J Cancer 47 : 1676-1681, 2011.

15) Pelzer U, Kubica K, Stieler J et al : A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26 suppl : 215s (abstr 4508), 2008.

16) Okusaka T, Ohkawa S, Isayama H et al : Randomized phase II trial of S-1 versus S-1 plus oxaliplatin (SOX) in patients with gemcitabine refractory pancreatic cancer. European Society for Medical Oncology 2012 Congress. Ann Oncol 23 suppl 9 : abstr 728, 2012.

17) Mizuno N, Yamao K, Komatsu Y et al : Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer. 2013 Gastrointestinal Cancers Symposium. J Clin Oncol 31 suppl : abstr 263, 2013.

18) Okusaka T, Ueno M, Omuro Y et al : Randomized phase II study comparing S-1 plus Leucovorin (SL) versus S-1 alone in patients with gemcitabine-refractory advanced pancreatic cancer (APC). European Cancer Congress 2013. Eur J Cancer 49 suppl 2 : S611 (abstr 2578), 2013.

19) Von Hoff D, Li CP, Wang-Gillam A et al : NAPOLI 1 : randomized phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer progressed on or following gemcitabine-based therapy. ESMO World Congress on Gastrointestinal Cancer 2014. (abstr O-0003), 2014.

20) Hurwitz H, Uppal N, Wagner SA et al : Johanna C. A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol 32 suppl : abstr 4000, 2014.

21) Neoptolemos JP, Stocken DD, Friess H et al : A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 : 1200-1210, 2004.

PubMed

22) Oettle H, Post S, Neuhaus P et al : Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial. JAMA 297 : 267-277, 2007.

PubMed

23) Oettle H, Neuhaus P, Hochhaus A et al : Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer : the CONKO-001 randomized trial. JAMA 310 : 1473-1481, 2013.

PubMed

24) Regine WF, Winter KA, Abrams RA et al : Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma : a randomized controlled trial. JAMA 299 : 1019-1026, 2008.

PubMed

25) Ueno H, Kosuge T, Matsuyama Y et al : A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer : Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 101 : 908-915, 2009.

26) Neoptolemos JP, Stocken DD, Bassi C et al : Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection : a randomized controlled trial. JAMA 304 : 1073-1081, 2010.

PubMed

27) Fukutomi A, Uesaka K, Boku N et al : JASPAC 01 : Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol 31 suppl : abstr 4008, 2013.

P.1814 掲載の参考文献

1) Doi R, Komoto I, Nakamura Y et al : Pancreatic Endocrine Tumor in Japan. Pancreas 28 : 247-252, 2004.

PubMed

2) Ito T, Sasano H, Tanaka M et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45 : 234-243, 2010.

PubMed

3) Yao JC, Shah MH, Ito T et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364 : 514-523, 2011.

PubMed

4) Raymond E, Dahan L, Raoul JL et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364 : 501-513, 2011.

PubMed

5) Moertel CG, Lefkopoulo M, Lipsitz S et al : Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced isletcell carcinoma. N Engl J Med 326 : 519-523, 1992.

PubMed

6) Ramanathan RK, Cnaan A, Hahn RG et al : Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 12 : 1139-1143, 2001.

PubMed

7) Strosberg JR, Fine RL, Choi J et al : First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117 : 268-275, 2011.

PubMed

8) Bajetta E, Zilembo N, Di Bartolomeo M et al : Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. Cancer 72 : 3099-3105, 1993.

PubMed

9) Aparicio T, Ducreux M, Baudin E et al : Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 37 : 1014-1019, 2001.

PubMed

10) Faiss S, Pape UF, Bohmig M et al : Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21 : 2689-2696, 2003.

11) Fjallskog ML, Granberg DP, Welin SL et al : Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92 : 1101-1107, 2001.

PubMed

12) Kulke MH, Wu B, Ryan DP et al : A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci 51 : 1033-1038, 2006.

PubMed

13) Rinke A, Muller HH, Schade-Brittinger C et al : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group. J Clin Oncol 27 : 4656-4663, 2009.

14) Moertel CG, Hanley JA : Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2 : 327-334, 1979.

PubMed

15) Engstrom PF, Lavin PT, Moertel CG et al : Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2 : 1255-1259, 1984.

PubMed

16) Sun W, Lipsitz S, Catalano P et al : Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors : Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23 : 4897-4904, 2005.

PubMed

17) Bajetta E, Catena L, Procopio G et al : Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59 : 637-642, 2007.

PubMed

18) Ekeblad S, Sundin A, Janson ET et al : Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13 : 2986-2991, 2007.

PubMed

19) Kulke MH, Stuart K, Enzinger PC et al : Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24 : 401-406, 2006.

PubMed

20) Mitry E, Baudin E, Ducreux M et al : Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81 : 1351-1355, 1999.

PubMed

21) Noda K, Nishiwaki Y, Kawahara M et al : Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 : 85-91, 2002.

PubMed

22) Yamaguchi T, Machida N, Kasuga A et al : Multicenter retrospective analysis of systemic chemotherapy in poorly differentiated neuroendocrine carcinoma of digestive system (Abstract #274). ASCO Gastrointestinal Cancers Symposium 2012.

23) Hainsworth JD, Spigel DR, Litchy S, Greco FA : Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma : a Minnie Pearl Cancer Research Network Study. J Clin Oncol 24 : 3548-3554, 2006.

PubMed

24) Moertel CG, Kvols LK, O'Connell MJ, Rubin J : Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68 : 227-232, 1991.

PubMed

25) Iwasa S, Morizane C, Okusaka T et al : Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol 40 : 313-318, 2010.

PubMed

P.1823 掲載の参考文献

1) World Health Organization : WHO Definition of Palliative Care, http://www.int/cancer/palliative/definition/en/

2) 厚生労働省 : がん対策推進基本計画, http://www.mhlw.go.jp/bunya/kenkou/gan_keikaku.html

3) 独立行政法人がん対策情報センター : 全国がん罹患モニタリング集計2010 年罹患数・率報告 (平成26年3月), http://ganjoho.jp/professional/statistics/monita.html

4) Temel JS, Greer JA, Muzikansky A et al : Early palliative care for patients with metastatic nonsmall-cell lung cancer. N Engl J Med 363 (8) : 733-742, 2010.

PubMed

5) Yuji Tachimori, Hiroshi Watanabe, Hoichi Kato et al : Hypercalcemia in patients with esophageal carcinoma. The pathophysiologic role of parathyroid hormone-related protein. Cancer 68 (12) : 2625-2629, 1991.

6) 工藤正俊, 有井滋樹, 猪飼伊和夫他 : 第18回全国原発性肝癌追跡調査報告 (2004～2005) (日本肝癌研究会追跡調査委員会). 肝臓 51 (8) : 460-484, 2010.

7) 恒藤暁 : 最新緩和医療学, p.46, 最新医学社, 東京, 1999.

8) Vainio A, Auvinen A : Prevalence of symptoms among patients with advanced cancer : an international collaborative study. Symptom Prevalence Group. J Pain Symptom Manage 12 (1) : 3-10, 1996.

9) 武田文和訳 : がんの痛みからの開放-WHO方式がん疼痛治療法-第2版, 金原出版, 東京, 1996.

10) 特定非営利活動法人日本緩和医療学会緩和医療ガイドライン委員会編 : 癌疼痛の薬物療法に関わるガイドライン2014年版, pp.25-28, 金原出版, 東京, 2014.

11) 武田文和訳 : 高カルシウム血症トワイクロス先生のがん患者症状マネージメント第2版, pp.223-227, 医学書院, 東京, 2012.

12) Larkin PJ, Sykes NP, Centeno C et al : The management of constipation in palliative care : clinical practice recommendation. Palliat Med 22 : 796-807, 2008.

PubMed

13) Miles C, Fellowes D. Goorman ML et al : Laxatives for the management of constipation in palliative care patients. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No. : CD003448

14) Xinopoulos D, Dimitroulopoulos D, Moschandrea I et al : Natural course of inoperable esophageal cancer treated with metallic expandable stents : quality of life and costeffectiveness analysis. J Gastroenterol Hepatol 19 : 1397-1402, 2004.

15) 宮崎達也, 宗田真, 田中成岳他 : 食道癌の終末期の特徴とターミナルケア, 臨外 65 (9) : 1238-1242, 2010.

16) Dorman A, Meisner S, Verin N et al : Self-expanding metal stents for gastroduodenal malignancies : systematic review of their clinical effectiveness. Endoscopy 36 : 543-550, 2004.

17) Khot UP, Lang AW, Murani K et al : Systematic review of the efficacy and safety of colorectal stents. Br J Surg 89 : 1096-1102, 2002.

18) Feuer DDJ, Broadley KE : Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database of Systematic Reviews 1999, Issue 3.

19) Hardy J, Ling J, Mansi J et al : Pitfalls in placebo-controlled trials in palliative care : dexamethasone for the palliation of malignant bowel obstruction. Palliat Med 12 : 437-442, 1998.

PubMed

20) 特定非営利活動法人日本緩和医療学会緩和医療ガイドライン委員会編 : 悪性消化管閉塞の薬物療法. がん患者の消化器症状の緩和に関するガイドライン2011年版, pp.45-51, 金原出版, 東京, 2011.

21) Laval G, Girerdier J, Lassauniere JM et al : The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients : Do they remove the obstruction? Palliative Medicine 14 : 3-10, 2000.

22) 志真泰夫, 山口研成, 宮田佳典他 : 末期癌患者における消化管閉塞に伴う消化器症状に対するOctreotide Acetateの臨床試験. 癌と化学療法 31 : 1377-1382, 2004.

Medical*Online

23) Mercadante S, Casuccio A, Mangione S : Medical treatment for inoperable malignant bowel obstruction : a qualitative systematic review. J Pain Symptom Manage 33 : 217-223, 2007.

PubMed

24) Ripamonti C, Mercadante S, Groff L, et al : Role of octoreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes : a prospective randomized trial. J Pain Symptom Manage 19 : 23-34, 2000.

25) Fearon K1, Strasser F, Anker SD et al : Definition and classification of cancer cachexia : an international consensus. Lancet Oncol 12 (5) : 489-495, 2011.

26) 特定非営利活動法人日本緩和医療学会緩和医療ガイドライン委員会編 : がん悪液質の概念と最近の動向. 終末期がん患者の輸液療法に関するガイドライン2013年度版, pp.46-52, 金原出版, 東京, 2013.

27) Morita T, Hyodo I, Yoshimi T et al : Association between hydration volume and symptoms in terminally ill cancer patients with abdominal malignancies. Ann Oncol 16 (4) : 640-647, 2005.

PubMed

28) 特定非営利活動法人日本緩和医療学会緩和医療ガイドライン委員会編 : 輸液は腹水による苦痛を悪化するか? 終末期がん患者の輸液療法に関するガイドライン2013年度版, p73-75, 金原出版, 東京, 2013.

29) Sakaida I, Kawazoe S, Kajimura K et al : Tolvaptan for improvement of hepatic edema : A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res 44 (1) : 73-82, 2014.

PubMed

30) Becker G, Galandi D, Blum HE : Malignant ascites : systematic review and guideline for treatment. Eur J Cancer 42 : 589-597, 2006.

PubMed

【前臨床試験】

P.1838 掲載の参考文献

1) 後発医薬品の生物学的同等性試験ガイドラインについて (医薬審第487号平成9年12月22日 (平成24年2月29日, 薬食審査発第0229第10号))

2) 柏瀬光寿他 : 実験的緑膿菌角膜感染モデルに対するLevofloxacin点眼液および眼軟膏の効果. あたらしい眼科 13 (2) : 249-253, 1996.

3) 秦野寛他 : 緑のう菌性角膜かいように対するDE-055 (Ofloxacin) 点眼液の予防および治療効果に関する実験的研究. 眼科臨床医報 79 (8) : 1553-1557, 1985.

4) Draize J H : Appraisal of the safety of chemicals in foods, drugs and cosmetics. Association of Food and Drug Officials of the United States, Texas, 1959.

5) 白瀬泰彦, 吐出豊秋編. 新毒性試験法-方法と評価-. 株式会社リアライズ社, 東京, 1985.

【臨床試験】

P.1859 掲載の参考文献

1) 山本啓二 : 抗血小板療法の実際. 血栓止血誌 19 (2) : 179, 2008.

2) 循環器疾患における抗凝固・抗血小板療法に関するガイドライン (2009年改訂版).

Medical*Online

3) Young-Hoon Jeong et al : Cilostazol to Overcome High On-Treatment Platelet Reactibity in Korean Patients Treated With Clopidogrel and Calcium-Channel Blocker. Circulation Journal 75 : 2534, 2011.

PubMed

4) 内山真一郎 : 脳梗塞患者におけるシロスタゾールとアスピリンのランダム化比較試験 (CSPS II) の成績. 臨床神経 50 : 832, 2010.

5) プレタール(R) OD錠 50mgおよびプレタール(R) OD 100mgの医薬品添付文書 (2013年2月改訂 (第6版)) (大塚製薬株式会社).

6) 奥田豊 : RACTABR技術を活用したOD錠の製剤設計. 薬剤学 71 (1) : 21, 2011.

7) 後発医薬品の生物学的同等性試験ガイドラインについて (平成9年12月22日医薬審第487号).

8) 後発医薬品の生物学的同等性試験ガイドライン等の一部改正について (平成13年5月31日医薬審発第786号).

9) 後発医薬品の生物学的同等性試験ガイドライン等の一部改正について (平成18年11月24日薬食審査発第1124004号).

10) 後発医薬品の生物学的同等性試験ガイドライン等の一部改正について (平成24年2月29日薬食審査発0229第10号).

11) 医薬品の臨床試験の実施の基準に関する省令 (平成9年3月27日厚生省令第28号).

12) 医薬品の臨床試験の実施の基準に関する省令の一部を改正する省令 (平成15年6月12日厚生労働省令第106号).

13) 医薬品の臨床試験の実施の基準に関する省令の一部を改正する省令 (平成16年12月21日厚生労働省令第172号).

14) 医薬品の臨床試験の実施の基準に関する省令の一部を改正する省令 (平成18年3月31日厚生労働省令第72号).

15) 医薬品の臨床試験の実施の基準に関する省令の一部を改正する省令 (平成20年2月29日厚生労働省令第24号).

16) ｢医薬品の臨床試験の実施の基準に関する省令｣の運用について (平成23年10月24日薬食審査発第1024第1号).

P.1869 掲載の参考文献

1) 日本皮膚科学会ガイドライン : 蕁麻疹診療ガイドライン, 日本皮膚科学会雑誌 121 (7) : 1339-1388, 2011.

2) 増田勝巳他 : スギ花粉大量飛散年における塩酸オロパタジン初期治療の有効性. 耳鼻咽喉科臨床 100 (2) : 137-144, 2007.

3) アレロック(R) 錠アレルギーを強力にブロック-その開発の歩み-. 医療 61 (6) : 437-438, 2007.

Medical*Online

4) アレロック(R) 顆粒0.5%の医薬品添付文書 (2013年8月改訂 (第2版) (協和発酵キリン株式会社).

5) 総論2 小児の薬のいろいろな形, 小児の薬の選び方・使い方改訂2版, pp.14-19, 株式会社南山堂, 東京, 2006.

6) 後発医薬品の生物学的同等性試験ガイドラインについて (平成9年12月22日医薬審第487号).

7) 後発医薬品の生物学的同等性試験ガイドライン等の一部改正について (平成13年5月31日医薬審発第786号).

8) 後発医薬品の生物学的同等性試験ガイドライン等の一部改正について (平成18年11月24日薬食審査発第1124004号).

9) 後発医薬品の生物学的同等性試験ガイドライン等の一部改正について (平成24年2月29日薬食審査発0229第10号).

10) 医薬品の臨床試験の実施の基準に関する省令 (平成9年3月27日厚生省令第28号).

11) 医薬品の臨床試験の実施の基準に関する省令の一部を改正する省令 (平成15年6月12日厚生労働省令第106号).

12) 医薬品の臨床試験の実施の基準に関する省令の一部を改正する省令 (平成16年12月21日厚生労働省令第172号).

13) 医薬品の臨床試験の実施の基準に関する省令の一部を改正する省令 (平成18年3月31日厚生労働省令第72号).

14) 医薬品の臨床試験の実施の基準に関する省令の一部を改正する省令 (平成20年2月29日厚生労働省令第24号).

15) 「医薬品の臨床試験の実施の基準に関する省令」のガイダンスについて (平成24年12月28日薬食審査発1228第7号).

16) 名取伸行他 : 内服薬の服用性と望まれる投与剤形に関する調査 : 患者を含めた職種間の比較. 医療薬学 34 (3) : 289-296, 2008.

Medical*Online

【臨床報告】

P.1876 掲載の参考文献

1) Ohkubo Y, Kishikawa H, Araki E et al : Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 28 : 103-117, 1995.

PubMed

2) United Kingdom Prospective Diabetes Study (UKPDS) Group : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 : 837-853, 1998.

3) 糖尿病データマネジメント研究会 http://jddm.jp/data/index-2013.html

4) Kahn SE, Haffner SM, Heise MA et al : Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 : 2427-2443, 2006.

PubMed

5) Oishi M, Yamazaki K, Okuguchi F et al : Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32). J Diabetes Investig 2014 ; DOI : 10.1111/jdi.12183.

6) Aikens JE, Piette JD : Longitudinal association between medication adherence and glycaemic control in Type 2 diabetes. Diabet Med 30 : 338-344, 2013.

PubMed

7) Meier JJ : GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8 : 728-742, 2012.

PubMed

8) アストラゼネカ株式会社 : 医薬品インタビューフォーム, ビデュリオン(R) 皮下注用2mg (第3版), 2014.

9) Diamant M, Van Gaal L, Guerci B et al : Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3) : 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol 2 : 464-473, 2014.

PubMed

10) Buse JB, Nauck M, Forst T et al : Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6) : a randomised, open-label study. Lancet 381 : 117-124, 2013.

PubMed

【Diagnosis】

P.1885 掲載の参考文献

1) Del Prato S : In search of normoglycaemia in diabetes : controlling postprandial glucose. Int J Obes Relat Metab Disord 26 (Suppl 3) : S9-S17, 2002.

2) The Diabetes Control and Complications Trial Research Group : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (14) : 977-986, 1993.

3) UK Prospective Diabetes Study (UKPDS) Group : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (9131) : 837-853, 1998.

4) Ohkubo Y, Kishikawa H, Araki E et al : Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 28 (2) : 103-117, 1995.

PubMed

5) DECODE Study Group : Glucose tolerance and mortality : Comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354 (9179) : 617-621, 1999.

6) Nakagami T : Hyperglycemia and mortality from all cause and from cardiovascular disease on five populations of Asian origin. Diabetologia 47 (3) : 385-394, 2004.

PubMed

7) Tominaga M, Eguchi H, Manaka H et al : Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22 (6) : 920-924, 1999.

8) Chiasson JL, Josse RG, Gomis R et al : Acarbose for prevention of type 2 diabetes mellitus : the STOP-NIDDM randomised trial. Lancet 359 (9323) : 2072-2077, 2002.

PubMed

9) Hanefeld M, Cagatay M, Petrowitsch T et al : Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients : meta-analysis of seven long-term studies. Eur Heart J 25 (1) : 10-16, 2004.

PubMed

10) Esposito K, Ciotola M, Carleo D et al : Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab 93 (4) : 1345-1350, 2008.

PubMed

11) Hanefeld M, Fischer S, Julius U et al : Risk factors for myocardial infarction and death in newly detected NIDDM : the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39 (12) : 1577-1583, 1996.

PubMed

12) Action to Control Cardiovascular Risk in Diabetes Study Group : Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (24) : 2545-2559, 2008.

13) ADVANCE Collaborative Group : Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (24) : 2560-2572, 2008.

14) Reaven PD, Emanuele N, Moritz T et al : Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Tria (l VADT). Diabetes Care 31 (5) : 952-957, 2008.

15) Currie CJ, Peters JR, Tynan A et al : Survival as a function of HbA (1c) in people with type 2 diabetes : a retrospective cohort study. Lancet 375 (9713) : 481-489, 2010.

PubMed

16) Goto A , A rah OA, G oto M e t al : Severe hypoglycemia and cardiovascular disease : systematic review and meta-analysis with bias analysis. BMJ 347 : f4533, 2013.

17) Marques JL, George E, Peacey SR et al : Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabet Med 14 (8) : 648-654, 1997.

PubMed

18) Galassetti P, Davis SN : Effects of insulin per se on neuroendocrine and metabolic counter-regulatory responses to hypoglycaemia. Clin Sci (Lond) 99 (5) : 351-362, 2000.

PubMed

19) Hoffman RP : Sympathetic mechanisms of hypoglycemic counterregulation. Curr Diabetes Rev 3 (3) : 185-193, 2007.

PubMed

20) Whitmer RA, Karter AJ, Yaffe K et al : Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301 (15) : 1565-1572, 2009.

PubMed

21) Monnier L, Mas E, Ginet C et al : Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295 (14) : 1681-1687, 2006.

PubMed

22) Azuma K, Kawamori R, Toyofuku Y et al : Repetitive fluctuations in blood glucose enhance monocyte adhesion to the endothelium of rat thoracic aorta. Arterioscler Thromb Vasc Biol 26 (10) : 2275-2280, 2006.

23) Azuma K, Toyofuku Y, Iesaki T et al : Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation. Biochem Biophys Res Commun 345 (2) : 688-693, 2006.

PubMed

24) Tanaka A, Azuma K, Toyofuku Y et al : Insulin and nateglinide reduce monocyte adhesion to endothelial cells in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation. Biochem Biophys Res Commun 350 (1) : 195-201, 2006.

PubMed

25) Kohnert KD, Augstein P, Zander E et al : Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 32 (6) : 1058-1062, 2009.

26) American Diabetes Association : Postprandial blood glucose. Diabetes Care 24 (4) : 775-778, 2001.

PubMed

27) The Diabetes Control and Complications Trial Research Group : Hypoglycemia in the diabetes control and complications trial. Diabetes 46 (2) : 271-286, 1997.

28) Schlichtkrull J, Munck O, Jersild M : The M-valve, an index of blood-sugar control in diabetics. Acta Med Scand 177 : 95-102, 1965.

29) Service FJ, Molnar GD, Rosevear JW et al : Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19 (9) : 644-655, 1970.

30) Kovatchev BP, Otto E, Cox D et al : Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 29 (11) : 2433-2438, 2006.

PubMed

31) http://www.childrenwithdiabetes.com/clinic/adrr.htm

32) Patton SR, Clements MA : Average daily risk range as a measure for clinical research and routine care. J Diabetes Sci Technol 7 (5) : 1370-1375, 2013.

33) 小出景子, 渥美義仁 : 薬剤師によるCS IIの導入継続指導の実践と新たな血糖変動指標の検討. 新薬と臨牀 62 (9) : 1577-1583, 2013.

34) McCall AL, Cox DJ, Brodows R et al : Reduced daily risk of glycemic variability : comparison of exenatide with insulin glargine. Diabetes Technol Ther 11 (6) : 339-344, 2009.

PubMed

35) Farhy LS, Ortiz EA, Kovatchev BP et al : Average daily risk range as a measure of glycemic risk is associated with mortality in the intensive care unit : a retrospective study in a burn intensive care unit. J Diabetes Sci Technol 5 (5) : 1087-1098, 2011.

36) Pitsillides AN, Anderson SM, Kovatchev B : Hypoglycemia risk and glucose variability indices derived from routine self-monitoring of blood glucose are related to laboratory measures of insulin sensitivity and epinephrine counterregulation. Diabetes Technol Ther 13 (1) : 11-17, 2011.

PubMed

P.1897 掲載の参考文献

1) 林田栄二他 : 全自動化学発光酵素免疫測定システム「ルミパルスPresto II」によるHCV抗体検出試薬の使用経験. 医学と薬学 58 (6) : 881-885, 2007.

Medical*Online

2) 大西重樹他 : HCV 抗体スクリーニング弱陽性例の検討-RIBA III c22p単バンド反応例の解析-. 医学検査 51 (3) : 229-233, 2002.

3) 廣瀬春香他 : 各種HCV抗体測定試薬の比較. 医学と薬学 65 (1) : 91-99, 2011.

Medical*Online

4) Leslie H, Tobler et al : Identification of a crossreactive epitope within hepatitis C virus core antigen : resolution by third-generation hepatitis C virus assays. TRANSFUSION 36 (6) : 582-583, 1996.

5) R. Lesniewski et al : Antibody to Hepatitis C Virus Second Envelope (HCV-E2) Glycoprotein -A New Marker of HCV Infection Closely Associated with Viremia. Journal of Medical Virology 45 : 415-422, 1995.

6) Pilar Leon et al : Use of Overlapping Synthetic Peptides to Characterize Samples from Blood Donors with Indeterminate Results to Hepatitis C Virus Core Antigen. Vox Sanguinis 75 : 32-36, 1998.

7) 平松久美子他 : HCV抗体とHCVコア抗原の組み合わせによる病院におけるC型肝炎スクリーニングの効率化. 医学と薬学 53 (3) : 347-354, 2005.

Medical*Online

8) Jean-Jacques Lefrere et al : Complete or partial seroconversion in immunocompetent individuals after self-limited HCV infection : consequences for transfusion. TRANSFUSION 44 : 343-348, 2004.

9) 田中純子他 : 平成24年度厚生労働科学研究費補助金 (肝炎等克服緊急対策研究事業) 肝炎ウイルス感染状況・長期経過と予後調査および治療導入対策に関する研究 -新たなC型肝炎ウイルス検査の手順について.

10) Tiziana Giubertf et al : Long-term follow-up of anti-hepatitis C virus antibodies in patients with acute non A non B hepatitis and different outcome of liver disease. Liver 12 : 94-99, 1992.

11) 美馬聡昭他 : 肝疾患における第3世代HCV抗体測定キット (RIA) の臨床的有用性. 医学と薬学 32 (6) : 1307-1313, 1994.

P.1908 掲載の参考文献

1) Okamoto F, Sohmiya K, Ohkaru Y et al : Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction, Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme. MB Clin Chem Lab Med 38 : 231-238, 2000.

PubMed

2) Kilcullen N, Viswanathan K, Das R et al : Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values. J Am Coll Cardial 50 : 2061-2067, 2007.

3) Seino Y, Ogata K, Takano T et al : Use of a whole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain : Comparison with rapid troponin T and myoglobin test. Am J Med 115 : 185-190, 2003.

PubMed

4) 田中孝生, 宗宮浩一, 弘田雄三他 : ヒト心臓脂肪酸結合蛋白 (H-FABP) 測定の臨床的意義. 医学と薬学 37 : 1367-1383, 1997.

Medical*Online

5) Thygesen K, Joseph S, Alpert, Harvey D et al : Universal definition of myocardial infarction. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Eur Heart J 28 : 2525-2538, 2007.

6) Koichi S, Takao T, Ryoichi T et al : Plasma and Urinary Heart-Type Cytoplasmic Fatty Acid-Binding Protein in Coronary Occlusion and Reperfusion Induced Myocardial injury Model. Journal of Molecular and Cellular Cardiology 25 : 1413-1426, 1993.

7) Hayashida N, Chihara S, Tayama E et al : Influence of renal function on serum and urinary heart fatty acid-binging protein levels. J cardiovasc Surg 42 : 735-740, 2001.

8) 小菅雅美 : 虚血性心疾患の性差. Medical Practice 30 : 996-1001, 2013.

Medical*Online

9) Takagi Y, Yasuda Y, Takahashi J et al : Importance of dual induction tests for coronary vasospasm and ventricular fibrillation in patients surviving out-of-hospital cardiac arrest. Circ J 73 : 767-769, 2009.

P.1914 掲載の参考文献

1) 西純一郎 : レンサ球菌感染症. 五十嵐隆編, 小児科臨床ピクシス25, 小児感染症-最新カレンダー&マップ, pp.158-163, 中山書店, 東京, 2011.

2) Kilian M : Streptococcus and enterococcus. Greenwood D, Slack RCB, Peutherer JF. Eds, Medical Microbiology 16th ed., Chapter16, pp.174-188, Churchill Livingstone, UK, 2002.

3) Michael AG, Gerber MD : Comparison of throat cultures and rapid strep tests for diagnosis of streptococcal pharyngitis. Pediatr Infect Dis J 8 : 820-824, 1989.

4) 川上小夜子, 斧康雄 : A群溶血性レンサ球菌抗原迅速診断キット5種類の基礎的検討-Streptococcus pyogenesの検出感度と特異性の評価. 臨床と微生物 37 : 699-704, 2010.

Medical*Online

5) 光野典子, 播智宏, 玉川信吉他 : A群レンサ球菌迅速診断キットの基礎的検討. 感染症誌 80 : 665-673, 2006.

6) 保科清, 都もと子, 小野正恵他 : クリアビューストレップAによるA群溶連菌抗原迅速診断の有用性に関する検討. 小児科臨床 48 : 2275-2278, 1995.

Medical*Online

7) 保科清 : A群溶連菌抗原検出法. 臨床と微生物 22 : 683-686, 1995.

Medical*Online

8) 藤川敏, 武谷広子 : 新しいA群レンサ球菌迅速診断キットCREARVIEW STREP Aの臨床的検討. 小児内科 27 : 1691-1694, 1995.

9) 甲田雅一, 宇田川郁子, 福原敦子他 : Streptococcus pyogenes (A群レンサ球菌) 迅速診断キットとしてのクリアビュー・ストレップ Aの評価. 臨床と微生物 24 : 365-369, 1997.

10) 藤田之彦, 岡田知雄, 荒川千賀子他 : Immunochromatographic assay (スタットチェックストレップA) によるA群βレンサ球菌抗原迅速検出法の検討. 医学と薬学 50 : 347-351, 2003.

11) 川上小夜子, 斧康雄, 柳川幸重他 : 免疫クロマグラフィー法による新規A群溶血性レンサ球菌抗原迅速検出キットの基礎的, 臨床的性能評価. JARMAM 14 : 9-16, 2003.

12) Dwight RJ, Edward LK : False-Positive Rapid Antigen Detection Test Results : Reduced Specificity in the Absence of Group A Streptococci in Upper Respiratory Tract. J Infect Diseases 183 : 1135-1137, 2001.

13) 佐藤成大 : レンサ球菌属, 腸球菌属. 山西弘一監, 平松啓一, 中込治編, 標準微生物学第9版, pp.243-249, 医学書院, 東京, 2005.

14) 木暮政雄, 外池千明 : A群溶連菌における分離培養での簡易菌数測定法の有用性についての検討. 医学と薬学 64 (6) : 923-929, 2010.

15) Steen H : The throat carrier rate of group A and other beta hemolytic streptococci among patients in general practice. Acta path Microbial Immunol Scand Sect B 93 : 347-351, 1985.

16) Michael AG, Martin FR, Donald RM : The Group A Streptococcal Carrier State. AJDC 142 : 562-565, 1988.

17) Vincent MT, Calestin N, Hassin AN : Pharyngitis. American Family Physician 69 (6) : 1465-1470, 2004.

P.1926 掲載の参考文献

1) 牛島廣治 : ウイルス性胃腸炎の診断法と疫学の過去. ウイルス 59 (1) : 75-90, 2009.

2) 中澤武司, 石和久 : 感染症診断の迅速化を目指して-感染症検査のPOCTを中心に, (2) 迅速キットの実際 (ウイルス). 臨床と微生物 34 (増刊号) : 127-129, 2007.

3) 厚生労働省医薬食品局食品安全部監視安全課長 : ノロウイルスの検出法について. 平成19年5月14日, 食安監発第0514004号 (2007).

P.1932 掲載の参考文献

1) 大平弘正他 : 自己免疫性胆管炎疾患での自己抗体とその病的意義. 肝胆膵 62 (4) : 629-637, 2011.

2) Neuberger J et al : Primary biliary cirrhosis. Gut Suppl : S73-S78, 1991.

PubMed

3) Kaplan MM : Primary biliary cirrhosis : past, present, and future. Gastroenterology 123 (4) : 1392-1394, 2002.

PubMed

4) 宮地清光他 : 原発性胆汁性肝硬変と自己抗体. Jpn J Clin Immunol 31 (1) : 47-55, 2008.

5) Coppel RL et al : Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis : dihydrolipoamide acetyltransferase. Proc Natl Acad Sci USA 85 (19) : 7317-7321, 1988.

6) Fussey SP et al : Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci USA 85 (22) : 8654-8658, 1988.

PubMed

7) Van de Water J et al : Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acethltransferase and inhibit enzyme function. J Immunol 141 (7) : 2321-2324, 1988.

PubMed

8) Fregeau DR et al : Antimitochondrial antibodies of primary biliary cirrhosis recognize dihydrolipoamide acyltransferase and inhibit enzyme function of the branched chain alpha-ketoacid dehydrogenase complex. J Immunol 142 (11) : 3815-3820, 1989.

PubMed

9) Surh CD et al : Reactivity of primary biliary cirrhosis sera with a human fetal liver cDNA clone of branched-chain alpha-keto acid dehydrogenase dihydrolipoamide acyltransferase the 52 kD mitochondrial autoantigen. Hepatology 9 (1) : 63-68, 1989.

10) Surh CD et al : Antimitochondrial autoantibodies in primary biliary cirrhosis recognize cross-reactive epitope (s) on protein X and dihydrolipoamide acethyltransferase of pyruvate dehydrogenase complex. Hepatology 10 (2) : 127-133, 1989.

11) Fregeau DR et al : Primary biliary cirrhosis. Inhibition of pyruvate dehydrogenase complex activity by autoantibodies specific for E1 alpha, a non-lipoic acid containing mitochondrial enzyme. J Immunol 144 (5) : 1671-1676, 1990.

PubMed

12) Feegeau DR et al : Inhibition of alpha-ketoglutarate dehydrogenase activity by a distinct population of autoantibodies recognizing dihydrolipoamide succinyltransferase in primary biliary cirrhosis. Hepatology 11 (6) : 975-981, 1990.

13) 竹村真理他 : MESACUP-2テストミトコンドリアM2の基礎的検討. 医学と薬学 46 (5) : 809-816, 2001.

Medical*Online

14) 丹野瑞木他 : 新しい抗ミトコンドリア抗体検出試薬ステイシア MEBLuxテストミトコンドリア M2の基礎性能および臨床的有用性の検討. 医学と薬学 67 (3) : 485-495, 2012.

Medical*Online

15) Jones DE : Autoantigens in primary biliary cirrhosis. J Clin Pathol 53 (11) : 813-821, 2000.

PubMed

16) Dahnrich C et al : New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem 55 (5) : 978-985, 2009.

17) 平田寛之他 : 自己抗体測定試薬エリアミトコンドリアM2 の基礎的検討. 医学と薬学69 (3) : 541-547, 2013.

18) Swiniarski S et al : Relevance of M2 IgG, IgM & IgA antibodies in primary biliary cirrhosis. Poster presented 10th Dresden Symposium on Autoimmunity, held in Dresden, September 22-25, 2011.

19) 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班 : 原発性胆汁性肝硬変 (PBC) の診療ガイドライン, 2012.

P.1943 掲載の参考文献

1) 庄司進一 : クレアチンキナーゼ (CK), CK-MB, CK-MM. 日本臨牀 67 (増刊号8) : 367-372, 2009.

Medical*Online

2) 星野忠, 中山智祥他 : 抗ミトコンドリアCK活性阻害抗体を用いた新規CK-MB活性測定法の臨床評価. 臨床化学 38 : 299-307, 2009.

Medical*Online

3) 上野芳人, 萩野良郎, 木野内喬 : ミトコンドリアCK. 日本臨牀 67 (増刊号8) : 373-377, 2009.

4) Soroida Y, Ohkawa R, Nakagawa H et al : Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. J Hepatol 57 : 330-336, 2012.

PubMed

5) 日本循環器学会・日本心臓病学会 : 急性冠症候群の診療に関するガイドライン, 2007.

6) ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction : Third universal definition of myocardial infarction. European Heart Journal 33 : 2551-2567, 2012.

PubMed